Table 1 Baseline patient characteristics.

From: Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate

Characteristic

ETV (n = 180)

TDF (n = 224)

P

Age, mean ± SD, years

45.4 ± 10.8

44.5 ± 11.4

0.51

Male sex, n (%)

106 (58.9)

120 (53.6)

0.31

BMI, kg/m2, median (IQR)

23.2 (21.2, 25.6)

23.2 (21.0, 25.5)

0.49

Cirrhosis, n (%)

67 (37.2)

78 (34.8)

0.68

Diabetes, n (%)

23 (12.8)

17 (7.6)

0.10

Hepatitis e antigen positivity, n (%)

118 (67.4)

128 (57.1)

0.038

HBV DNA, log10(copies/mL), median (IQR)

7.71 (6.74, 8.64)

7.44 (6.33, 8.53)

0.32

Platelet, × 103/μL, median (IQR)

158 (112, 198)

155 (115, 200)

0.93

Albumin, g/dL, median (IQR)

4.1 (3.7, 4.5)

4.2 (3.8, 4.5)

0.68

Bilirubin, mg/dL, median (IQR)

0.77 (0.54, 1.33)

0.78 (0.55, 1.07)

0.36

PT, INR, median (IQR)

1.06 (1.00, 1.22)

1.06 (1.00, 1.14)

0.30

ALT, IU/L, median (IQR)

83.5 (38.3, 154.0)

85.0 (42.0, 160.5)

0.54

Creatinine, mg/dL, median (IQR)

0.9 (0.8, 1.1)

0.9 (0.7, 1.0)

0.013

Child–Pugh score, median (IQR)

5.0 (5.0, 6.0)

5.0 (5.0, 5.0)

0.012

GAG-HCC score, median (IQR)

85.9 (72.6, 107.8)

82.7 (65.6, 105.9)

0.14

CU-HCC score, median (IQR)

8.5 (7.0, 23.5)

7.0 (4.0, 20.5)

0.31

PAGE-B score, median (IQR)

14.0 (10.0, 16.0)

12.0 (8.0, 16.0)

0.40

Treatment response at 1 year, n (%)

Biochemical

116 (67.4)

132 (62.3)

0.33

Serologicala

80 (49.7)

93 (49.5)

 > 0.99

Virologicalb

117 (68.4)

170 (79.4)

0.018

Sustained virological suppression, n (%)

85 (48.0)

126 (62.4)

0.005

Duration of follow-up, month, median (IQR)

64.0 (30.5, 84.3)

49.1 (37.7, 62.2)

 < 0.001

  1. ETV entecavir, TDF tenofovir disoproxil fumarate, SD standard deviation, IQR interquartile ranges, BMI body mass index, HBV hepatitis B virus, PT prothrombin time, INR international normalized ratio, ALT alanine aminotransferase, GAG-HCC guide with age, gender, HBV DNA core promoter mutations and cirrhosis, CU Chinese University.
  2. aHepatitis e antigen seroconversion.
  3. bUndetectable HBV DNA by polymerase chain reaction with a detection limit of 10 IU/mL.
Back to article page